Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 9/20 | 0.75 |
| ▸ | DHODH | Q02127 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23590256 | 0.89 | DHODH (0.74) | PLA2G2ADHODHALDH1A1MEN1KMT2A | |
| SCHEMBL5792945 | 0.86 | PLA2G2A (0.78) | PLA2G2ADHODHALDH1A1MEN1KMT2A | |
| SCHEMBL28475970 | 0.86 | PLA2G2A (0.78) | PLA2G2ADHODHALDH1A1KDM4EGAA | |
| SCHEMBL26074102 | 0.81 | PLA2G2A (0.64) | PLA2G2ADHODHALDH1A1MEN1KMT2A | |
| SCHEMBL23590113 | 0.80 | DHODH (0.60) | PLA2G2ADHODHALDH1A1MEN1KMT2A | |
| SCHEMBL28693800 | 0.79 | KDM4E (0.72) | PLA2G2ADHODHALDH1A1MEN1KMT2A | |
| SCHEMBL26075568 | 0.79 | APP (0.49) | PLA2G2ADHODHALDH1A1MEN1KMT2A | |
| SCHEMBL23590281 | 0.79 | DHODH (0.59) | PLA2G2ADHODHALDH1A1MEN1KMT2A | |
| SCHEMBL23590067 | 0.78 | PLA2G2A (0.82) | PLA2G2ADHODHALDH1A1MEN1KMT2A | |
| SCHEMBL29617671 | 0.78 | PLA2G2A (0.82) | PLA2G2ADHODHALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | PLA2G2A 1679/4885DHODH 1/4885ALDH1A1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.